About Join the Founding Community

The science of health optimization is advancing faster than the infrastructure built to support it.

We built Healthspanners because that infrastructure needed to exist.

The Founder

Built by Someone Who Lives It

Eric has viewed human biology as a programmable system since childhood. That conviction drove a lifelong practice of actively managing his health, tracking biomarkers for decades to measure the exact return on every intervention.

But years into building and then selling his previous company, the demands of scale overwhelmed those systems. Sleep deprivation and constant travel took a compounding physical toll, culminating in a bulging disc in his neck that made every movement excruciating.


Getting out of pain required a systemic overhaul. To solve the mechanical problem, he founded Aescape, a robotics wellness company that raised over $130M, partnered with Tom Brady, and scaled to locations like Equinox and the Four Seasons. To solve the biological problem, he built a physical and regenerative medicine protocol to address the condition at its root. What emerged was a focus for health optimization he had never experienced before.

Today, Eric operates with the physical capacity of his twenties and the wisdom of someone who has lived it. His conviction is absolute: the people who see the greatest returns are those who own the process, build the baseline, run the protocols, and show up when the science moves. He does not speculate on longevity escape velocity, but he understands the mathematics of compounding returns. The better the foundation built today, the greater the likelihood of capturing the breakthroughs arriving tomorrow.

The Program

What the Protocol Looks Like

Every element of the program is designed to build on the one before it.

~200
Biomarkers at Intake

A metabolic, hormonal, cardiovascular, genetic, inflammatory, and functional baseline. Every protocol builds on what came before.

9+
Body Systems

A deliberate, evidence-gated progression across every major system. Over three years, nothing significant is left unaddressed.

5
Members Per Cohort

Small enough that everyone is known. Large enough for real clinical comparison. The cohort is the accountability layer.

3
Year Commitment

Long enough for the compounding to become visible. The founding commitment is locked at today's price from day one.

The protocols are developed and continuously iterated by a dedicated clinical team. Medical Director oversight ensures rigor across every intervention. Each member's Clinical Lead manages their individualized protocol from intake through every quarterly cycle, building a longitudinal clinical picture that deepens in value with every year.

The Team

Who We Are

Eric Litman, Founder

Eric Litman

Founder

Founded Aescape, Medialets, Viaduct. Co-founded Proxicom and digitalNATION. Cohort 1, member 1.

Dan Burns, Co-Founder

Dan Burns

Co-Founder

Former Team USA athlete. Led sales at Aescape and international business development at Bird.

The Opportunity

What's Coming

This is why the timing of this matters.

Muscle as Medicine

Drugs like garetosmab and trevogrumab are approaching clinical availability to add lean muscle to otherwise healthy people. Muscle is the largest endocrine organ in the body. Adding it isn't cosmetic. It's metabolic, with cascading effects on insulin sensitivity, bone density, inflammation, and functional capacity over time.

Cardiovascular Risk, Resolved

PCSK9 inhibition gene therapy has the potential to reduce cardiovascular disease risk to near zero with a single treatment. Not managed. Not mitigated. Fundamentally resolved.

Cellular Reprogramming

Early, but if it delivers on the research, it will change how we experience aging itself. Not by slowing decline, but by resetting the biological systems that drive it.

In Silico Medicine

Foundation models are shifting biology from an observational science to an engineering discipline. By combining systems-level cellular simulations with closed-loop robotic labs, AI is now designing de novo therapeutics and predicting clinical toxicity before a single physical experiment is run.

These are active clinical programs and funded research happening now. The question isn't whether these interventions arrive. It's whether we're in position to act on them when they do.

The Cohort

The Cohort Effect

When five people work through the same protocol simultaneously, something happens that no individual clinical relationship can produce. One member's response to a protocol adjustment becomes an insight that informs the Clinical Lead's approach for everyone else. Five people generating data on the same interventions, measured on the same cadence, creates a feedback loop that makes every protocol sharper and every quarter more precise.

Each quarter builds on the last. That's the curve. And it starts with the decision to begin.

This begins with the right people.
We'd like to know if you're one of them.

Join the Founding Community